论文部分内容阅读
目的探讨肺心病急性加重期凝血特点及奥扎格雷钠的干预作用。方法选取2013年2月至2015年1月郑州大学第一附属医院收治的肺心病加重期患者70例为研究对象,随机分为观察组和对照组各35例,并选择35例健康志愿者纳入健康组,对照组给予常规治疗,观察组在此基础上加用奥扎格雷钠治疗,比较三组治疗前后凝血酶原时间(PT)、纤维蛋白原(FIB)、D-二聚体水平,同时采用卡氏评分表(KPS)、匹兹堡睡眠质量指数表(PSQI)分析两组生活质量及睡眠质量,并记录不良反应发生率。结果治疗前观察组、对照组PT、FIB低于健康组(P<0.05),观察组、对照组D-二聚体较健康组高(P<0.05),治疗后两组PT、FIB升高,D-二聚体下降,观察组上述指标与健康组比较无显著差异(P>0.05),对照组上述指标与健康组比较有统计学意义(P<0.05);治疗后观察组KPS评分(88.45±2.17)分高于对照组,观察组PSQI评分(7.21±0.51)分低于对照组(P<0.05);两组不良反应发生率8.6%、5.7%比较无显著差异(P>0.05)。结论肺心病急性加重期凝血功能较健康组低,奥扎格雷钠可有效改善患者凝血功能、生活质量、睡眠质量,值得在临床推广应用。
Objective To investigate the characteristics of coagulation in acute exacerbation of chronic cor pulmonale and the intervention of ozagrel sodium. Methods From February 2013 to January 2015, 70 patients with exacerbations of pulmonary heart disease admitted to the First Affiliated Hospital of Zhengzhou University were enrolled in this study. The patients were randomly divided into observation group (35 cases) and control group (35 cases), and 35 healthy volunteers The healthy group and the control group were given routine treatment. The observation group was treated with ozagrel sodium on the basis of this. The prothrombin time (PT), fibrinogen (FIB) and D-dimer level were compared between the three groups before and after treatment. At the same time, KPS and Pittsburgh Sleep Quality Index (PSQI) were used to analyze the quality of life and quality of sleep, and the incidence of adverse reactions was recorded. Results Before treatment, the PT and FIB in the control group were lower than those in the healthy group (P <0.05), and the D-dimer in the observation group and the control group were higher than those in the healthy group (P <0.05) , D-dimer decreased in the observation group compared with the healthy group there was no significant difference (P> 0.05), the above indicators in the control group and the healthy group was statistically significant (P <0.05); after treatment, the observation group KPS score 88.45 ± 2.17) in the observation group was higher than that in the control group, and the PSQI score (7.21 ± 0.51) in the observation group was lower than that of the control group (P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions of 8.6% and 5.7% . Conclusion Cor Pulmonale in patients with acute exacerbation of pulmonary heart disease is lower than healthy people. Ozagrel sodium can effectively improve the coagulation function, quality of life and quality of sleep in patients with pulmonary heart disease. It is worthy of clinical application.